Evidence map›Paper›PMID 40786512›Full record

ArticleFrontiers in oncology2025

Remarkable tumor response to Iruplinalkib in a 14-year-old girl with

Jiahao Wang, Qingdi Du, Xueyan Sun, Rong Tao, Zuojuan Zhang, Wei Li, Wenjing Liu, Li Wei, Zongsheng Tian, Xueliang Xu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiahao Wang *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Qingdi Du *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Xueyan Sun *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Rong TaoDepartment of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Zuojuan ZhangDepartment of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Wei LiDepartment of Thoracic Surgery, Linyi People's Hospital, Linyi, China.
Wenjing LiuDepartment of Pathology, Linyi People's Hospital, Linyi, China.
Li Wei *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Zongsheng Tian *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Xueliang Xu *Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapies for anaplastic lymphoma kinase (

Indexed as

ALK fusion gene mutationcase reportIruplinalkibnon-small cell lung cancertargeted therapy

Identifiers

PMID40786512
PMCPMC12331475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.